chemoimmunotherapy for advanced gastrointestinal carcinomas: A successful combination of gene therapy and cyclophosphamide

4Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The combination of a single low dose of cyclophosphamide (Cy) with the adenovirus-mediated gene transfer of interleukin-12 (AdIL-12) might represent a successful therapy for experimental gastrointestinal tumors. This approach has been proven to revert immunosuppressive mechanisms elicited by cancer cells and to synergistically promote antitumor immunity. In addition, this therapeutic regimen has been shown to be more efficient in achieving complete tumor regressions in mice than the application of a metronomic schedule of Cy plus AdIL-12. © 2012 Landes Bioscience.

Cite

CITATION STYLE

APA

Malvicini, M., Piccioni, F., Bayo, J., Fiore, E., Atorrasagasti, C., Alaniz, L., … Mazzolini, G. (2012). chemoimmunotherapy for advanced gastrointestinal carcinomas: A successful combination of gene therapy and cyclophosphamide. OncoImmunology. https://doi.org/10.4161/onci.21651

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free